Delving into the Latest Updates on HOLOPACK Verpackungstechnik GmbH with Synapse

概览

疾病领域	数量

内分泌与代谢疾病	1
血液及淋巴系统疾病	1
神经系统疾病	1

排名前五的药物类型	数量

小分子化药	2
重组蛋白	1
化学药	1

排名前五的靶点	数量

TNF-α(肿瘤坏死因子α)	1
ADRA2 x mAChRs	1
mAChRs(毒蕈碱型乙酰胆碱受体家族)	1

关联

4

项与 HOLOPACK Verpackungstechnik GmbH 相关的药物

Ferric Pyrophosphate Citrate

焦磷酸铁柠檬酸

靶点-

作用机制

铁调节

在研机构

Rockwell Medical, Inc. [+3]

原研机构

Rockwell Medical, Inc.

在研适应症

缺铁性贫血 [+3]

非在研适应症

难治性缺铁性贫血 [+2]

最高研发阶段批准上市

首次获批国家/地区

日本

首次获批日期1965-06-05

Aceclidine

醋克利定

靶点

mAChRs

作用机制

mAChRs激动剂

在研机构

LENZ Therapeutics, Inc. [+2]

原研机构

LENZ Therapeutics, Inc.

在研适应症

老花眼

非在研适应症-

最高研发阶段申请上市

首次获批国家/地区-

首次获批日期-

Tanfanercept

特那西普

靶点

TNF-α

作用机制

TNF-α抑制剂

在研机构

BINEX Co., Ltd. [+2]

原研机构

HANALL BIOPHARMA Co., Ltd.

在研适应症

干眼症

非在研适应症

葡萄膜炎 [+1]

最高研发阶段临床3期

首次获批国家/地区-

首次获批日期-

5

项与 HOLOPACK Verpackungstechnik GmbH 相关的临床试验

CTR20202142

/ Active, not recruiting临床3期

一项评价HBM9036（HL036）滴眼液（0.25%）与安慰剂相比治疗中国中、重度干眼患者的有效性和安全性的3期、多中心、随机、双盲、安慰剂对照研究

评价HBM9036（HL036）滴眼液（0.25%）与安慰剂相比治疗中国中、重度干眼患者的有效性和安全性。

开始日期2021-02-25

申办/合作机构

BINEX Co., Ltd.

[+3]

CTR20202200

/ Active, not recruiting临床3期

在中国CKD-5HD患者中通过血液透析液长期给予Triferic的随机、安慰剂对照研究。

主要目的：在中国CKD-5HD患者中确定Triferic经血液透析液长期给药在防止发生缺铁和维持红细胞生成及血红蛋白浓度所需铁供应方面的有效性与安全性。

开始日期2020-11-27

申办/合作机构

杭州泰格医药技术咨询有限公司

[+2]

CTR20182219

/ Completed临床2期

评价HBM9036(HL036)滴眼液(0.25%)与安慰剂相比治疗中、重度干眼患者的有效性和安全性的II期、多中心、随机、双盲、安慰剂对照研究

比较HBM9036(HL036)滴眼液与安慰剂治疗干眼的有效性和安全性。

开始日期2019-03-24

申办/合作机构

BINEX Co., Ltd.

[+3]

100 项与 HOLOPACK Verpackungstechnik GmbH 相关的临床结果

登录后查看更多信息

0 项与 HOLOPACK Verpackungstechnik GmbH 相关的专利（医药）

登录后查看更多信息

3

项与 HOLOPACK Verpackungstechnik GmbH 相关的文献（医药）

2025-04-03·EJPPS EUROPEAN JOURNAL OF PARENTERAL AND PHARMACEUTICAL SCIENCES

Recovery of Encapsulated Bacterial Spores in Styrene-Butadiene Copolymer to Validate Blow-Fill-Seal Processes

作者: Jahn, Michael Karl ; Gigerb, Samira ; Bauera, Bernadette ; Reinhardta, Natalie ; Goverdeb, Marcel

In this study, a detection method for Bacillus atrophaeus spores encapsulated in blow-fill-seal (BFS) containers made from extruded copolymer was developed and validated. Bacillus atrophaeus spores, known for their high thermal resistance, serve as model organisms for evaluating sterilization efficacy in polymer extrusion processes. A method for quantifying viable spores post-extrusion was established. The usually used low density polyethylene (LDPE) 3020D was replaced by comparable Styrolux® 656C styrene-butadiene copolymers (SBC) that could be dissolved at room temperature using toluene. Finally, SBC samples could be dissolved in toluene and B. atrophaeus spores were added to check the recovery rate. A standard filtration was developed – which did not reduce the bacterial spore count – using a Milliflex Plus Pump Single Head Kit with PVDF filters including rinsing with ethanol and NaCl-peptone buffer to reactivate bacterial spores. All positive controls showed a good recovery rate while the treatment with toluene alone yielded a recovery rate of 30% to 52%. This reduction decreased when the SBC was added to the solvent toluene giving a recovery rate of 57%. The method developed thus yielded an acceptable recovery of bacterial spores of B. atrophaeus with the copolymer Styrolux® 656C and can therefore be used to enumerate bacterial spores in BFS-manufactured containers to evaluate the efficacy of the extrusion process in eliminating microorganisms, allowing determination of the corresponding killing kinetics.

Pharmazeutische Industrie

Validation of a production and distribution system for water for injection and purified water

作者: Pfafflin, Annette

In this contribution the results of the validation of a water treatment system consisting of Reverse Osmosis and Continuous Deionization will be described.Often discussed problems about nutrient media, correlation of TOC (Total Organic Carbon) and the number of bacteria, need of distillation in addition to osmosis to achieve the quality of water for injection etc. will be treated.

Pharma Technologie Journal

Validation of a water treatment system for water for injection and purified water

作者: Pfafflin, Annette

In the following contribution the results of the validation of a water treatment system consisting of Reverse Osmosis and Continuous Deionization will be described.Often discussed problems about nutrient media, correlation of TOC (Total Organic Carbon) and the number of bacteria, need of distillation in addition to osmosis to achieve the quality of water for injection etc. will be treated.

100 项与 HOLOPACK Verpackungstechnik GmbH 相关的药物交易

登录后查看更多信息

100 项与 HOLOPACK Verpackungstechnik GmbH 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2025年05月13日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床1期

1

3

临床3期

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

特那西普 ( TNF-α )	干眼症更多	临床3期
乙酰克里定/溴莫尼定 ( ADRA2 x mAChRs )	老花眼更多	临床3期
焦磷酸铁柠檬酸	肾病更多	临床3期
醋克利定 ( mAChRs )	老花眼更多	临床1期